NIH — and some fa­mil­iar play­ers — back a PhII Alzheimer’s gam­ble in an­oth­er stab at the amy­loid hy­poth­e­sis

Cog­ni­tion Ther­a­peu­tics has a $76 mil­lion grant from the NIH to try out its ap­proach to guard­ing against the synap­tic dam­age be­hind the cas­cade of events that brings on Alzheimer’s. And they’re em­ploy­ing some well-known play­ers in the field for the work.

The New York-based biotech re­port­ed Mon­day morn­ing that the NIH has com­mit­ted to back­ing their Phase II tri­al for CT1812 in 540 ear­ly-stage pa­tients over the next 3 years. Cog­ni­tion says they’ll be car­ry­ing out the study along with the NIH-fund­ed Alzheimer’s Clin­i­cal Tri­al Con­sor­tium.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER